Company / Cost of Revenue
Tandem Diabetes Care Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$468.7M
FY2025
5-year range
$168.1M / $468.7M
FY2021-FY2025
Trend
+4.0%
vs FY2024
Sector context
#64 of 113
Health Care
What the data says
At $469M, Tandem Diabetes Care's cost of revenue ranks #50 of 113 in the Health Care sector. Cost of Revenue has increased for 8 consecutive years, from $46M in FY2017 to $469M in FY2025.
Based on SEC 10-K filings.
$469M in FY2025 with a 5-year CAGR of +37.9%.
Increased from $380M to $469M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +25.3%
- 5-Year CAGR
- +37.9%
- 10-Year CAGR
- -
Sector benchmark
#50 of 113 in Health CareTop 43% of 113This company $468.7M Sector average $11.3B
▼
-95.9% below sector average
Key checks
Key Insights
- Tandem Diabetes Care's cost of revenue has grown for 8 consecutive years.
- 5-year CAGR of +37.9%, indicating consistent growth.
- In FY2025, cost of revenue increased 4.0% year-over-year.
- Ranks #64 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $468.7M | +4.0% |
| FY2024 | $450.6M | +18.6% |
| FY2023 | $380.0M | +59.5% |
| FY2022 | $238.3M | +41.8% |
| FY2021 | $168.1M | +78.7% |
| FY2020 | $94.0M | +48.1% |
| FY2019 | $63.5M | +4.7% |
| FY2018 | $60.7M | +31.1% |
| FY2017 | $46.3M | -23.7% |
| FY2016 | $60.7M | +31.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026